| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Jon Congleton
Also a director
President, Chief Executive Officer, and Director
|
62 |
Since 2020
6 years
|
$5,544,727 | |
|
Adam Levy
Chief Financial Officer and Secretary
|
47 | Not stated | $2,203,096 | |
|
Eric Warren, R.Ph.
Chief Commercial Officer
|
53 |
Since 2025
1 year
|
Not reported | |
|
James J. Ferguson III
Chief Medical Officer
Title from the Form 8-K dated Aug 10, 2026
|
Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 8, 2026 · updated by the 8-Ks of Oct 19, 2026 and Nov 4, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Glenn P. Sblendorio
Board chair
|
70 |
2023
3 years
|
Independent |
Audit Committee
|
Amicus Therapeutics, Inc., 4D Molecular Therapeutics, Inc. | $331,310 | |
|
Jon Congleton
CEO
|
62 |
2020
6 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Brian Taylor Slingsby
|
49 |
2019
7 years
|
Independent |
Compensation Committee
Nominating and Corporate Governance Committee · Chair
|
None stated | Not stated | |
|
Srinivas Akkaraju
|
58 |
2021
5 years
|
Independent |
Nominating and Corporate Governance Committee
|
vTv Therapeutics Inc., Alumis Inc., Inventiva S.A. | Not stated | |
|
Daphne Karydas
|
53 |
2023
3 years
|
Independent | None stated | COMPASS Pathways plc | $307,043 | |
|
Alexander Gold
|
60 |
2024
2 years
|
Independent | None stated | None stated | $305,276 | |
|
Kristine Peterson
Joined Oct 19, 2026
|
- | - | Independent |
Audit Committee
|
- | - | |
|
Lonnel Coats
Joined Oct 19, 2026
|
- | - | Independent |
Compensation Committee
|
- | - | |
|
Derek DiRocco
Leaving Dec 31, 2026
|
45 |
2022
4 years
|
Independent |
Compensation Committee
|
Evommune, Inc., Acrivon Therapeutics, Inc. | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 8, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...